Lectures and seminars Seminar: “Dark” Pathways of Protein Transnitrosylation Mediate Synapse Loss in Alzheimer’s Disease: Mechanism and Potential Treatment

22-08-2024 4:00 pm - 5:00 pm Add to iCal
Campus Solna Bioclinicum J3:14 (Kerstin Hagenfeldt)

Welcome to the seminar with Stuart A. Lipton, MD, PhD.
Professor and Founding Director, Neurodegeneration New Medicines Center; Step Family Foundation Endowed Chair,
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.

Stuart A. Lipton, MD, PhD. Photo: Unknown.

Professor Lipton described the mechanism of action and contributedto the clinical development of the approved Alzheimer’s drug memantine. He also discovered the posttranslational redox modification known as protein S-nitrosylation.

Recently, Lipton and colleagues combined memantine with S-nitrosylation chemistry to produce a new drug called NitroSynapsin, which displays disease-modifying activity in animal models of Alzheimer's disease, both protecting synapses and improving neurobehavioral deficits.

Contact